HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment

Por Groheux, D, Giacchetti, S, Hatt, M, Marty, M, Vercellino, L, de Roquancourt, A, Cuvier, C, Coussy, F, Espié, M, Hindié, E
Publicado em 2013

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen

Por Giacchetti, S, Porcher, R, Lehmann-Che, J, Hamy, A-S, de Roquancourt, A, Cuvier, C, Cottu, P-H, Bertheau, P, Albiter, M, Bouhidel, F, Coussy, F, Extra, J-M, Marty, M, de Thé, H, Espié, M
Publicado em 2014

Clinical value of R-spondins in triple-negative and metaplastic breast cancers

Por Coussy, F, Lallemand, F, Vacher, S, Schnitzler, A, Chemlali, W, Caly, M, Nicolas, A, Richon, S, Meseure, D, El Botty, R, De-Plater, L, Fuhrmann, L, Dubois, T, Roman-Roman, S, Dangles-Marie, V, Marangoni, E, Bièche, I
Publicado no Br J Cancer (2017)